TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01532544
Drug: Ilomedin and Integrilin
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous infusion
Study: NCT05004506
Drug: Adductor Canal Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
Study: NCT05004506
Drug: Intra-articular Injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
Study: NCT01789528
Drug: CAZ-AVI
Normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01789528
Drug: CXL
Normalized name: CXL-1020
DrugBank: CXL-1020 (DB15326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01299571
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT01805544
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
Study: NCT00199225
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00199225
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00693472
Drug: Preladenant
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant, one 25 mg capsule, administered orally every 12 hours
Study: NCT00693472
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Study: NCT02768714
Drug: Eurofarma's pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
Study: NCT02032095
Drug: GB-0998
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790555
Drug: Diazepam/placebo
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003231
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003231
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00690170
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
Study: NCT00690170
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
Study: NCT00690170
Drug: Ketamine and Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)
Study: NCT04375397
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
Study: NCT04754685
Drug: Intra-articular injection of platelet-rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
Study: NCT01304329
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose oral administration
Study: NCT04213170
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
Study: NCT01797380
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 mg po daily for duration of double-blind portion of trial
Study: NCT04423601
Drug: SHR6390 tablet
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of SHR6390 or co-administered with itraconazole.
Study: NCT04423601
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg itraconazole was administered in the morning.
Study: NCT03508323
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20mg/qd
Study: NCT00002239
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002239
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002239
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002239
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002239
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05052437
Drug: Utidelone
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
Study: NCT01948232
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor
Study: NCT00645905
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
Study: NCT00645905
Drug: placebo for adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
Study: NCT03561701
Drug: Oteseconazole (VT-1161)
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oteseconazole (VT-1161) 150mg capsule
Study: NCT01243567
Drug: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
Study: NCT01243567
Drug: latanoprost 0.005% ophthalmic solution
Normalized name: Latanoprost 0.005% Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
Study: NCT03233295
Drug: Vitamin D3 B.O.N. Injection
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholecalciferol 200,000IU
Study: NCT03990805
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline, 1 time injection
Study: NCT03077555
Drug: Zoely
Normalized name: zinc oxide
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
Study: NCT02784015
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02784015
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02784015
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02784015
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02784015
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02784015
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00607854
Drug: Ibritumomab Tiuxetan (Zevalin)
Normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)
Study: NCT00624780
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150-300 mg given twice a day
Study: NCT00624780
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam 3-4 mg given twice a day
Study: NCT00624780
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450-600 mg given twice a day
Study: NCT03510351
Drug: Ceftolozane-Tazobactam
Normalized name: ceftolozane-tazobactam
DrugBank: Tazobactam (DB01606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
Study: NCT02402686
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
Study: NCT03476616
Drug: Valsartan (-based therapy) arm
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
Study: NCT03883334
Drug: Metisoprinol
Normalized name: Methisoprinol
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunodulator
Study: NCT01968057
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT01968057
Drug: Ciclosporin
Normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04015869
Drug: Allopregnanolone
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neurosteroid
Study: NCT02547493
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept started on frst day
Study: NCT01812369
Drug: GEMCITABINE CISPLATINE
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00837876
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg taken by mouth 1 time per day.
Study: NCT01199276
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
Study: NCT01199276
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
Study: NCT00004165
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03854890
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
Study: NCT00990145
Drug: EDP-322
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03706703
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
Study: NCT03706703
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
Study: NCT03706703
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
Study: NCT03706703
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
Study: NCT01656629
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mcg subq daily for 3 months
Study: NCT01656629
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg weekly for 3 months
Study: NCT04900948
Drug: Pimecrolimus cream 1%
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
Study: NCT00359567
Drug: palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Study: NCT00359567
Drug: granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Study: NCT01219933
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
Study: NCT01219933
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: background therapy: 8 mg/kg iv every 4 weeks
Study: NCT00657384
Drug: acid tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
Study: NCT02911688
Drug: gamma tocopherol
Normalized name: Gamma tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
Study: NCT01837667
Drug: LB-100 for Injection
Normalized name: milbemycin oxime
DrugBank: LB-100 (DB15412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
Study: NCT01837667
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
Study: NCT04218071
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib at protocol-specified doses for given platelet count
Study: NCT04218071
Drug: 9-ING-41
Normalized name: ING-1
DrugBank: ING-1 (DB05831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-
Study: NCT00680758
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients
Study: NCT00680758
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients
Study: NCT00680758
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients
Study: NCT03149003
Drug: DSP-7888 Dosing Emulsion
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
Study: NCT03149003
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
Study: NCT02177409
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00975065
Drug: vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)
Normalized name: vildagliptin 50 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: vildagliptin 50 mg bid plus metformin 1500mg
Study: NCT00975065
Drug: metformin 1500mg plus metformin 500mg or 1000mg (Diabex)
Normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 1500mg plus metformin 500mg or 1000mg
Study: NCT02916147
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02916147
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02634021
Drug: dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous loading of dexmedetomidine for 1 mcg/kg
Study: NCT02634021
Drug: midazolam group
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous loading of midazolam for 0.1 mg/kg
Study: NCT00927615
Drug: abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg body weight (intracoronary)
Study: NCT00927615
Drug: abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg body weight (intravenous)
Study: NCT04172961
Drug: nanomicellular cyclosporine 0.09%
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Study: NCT04172961
Drug: Lifitegrast
Normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Study: NCT00987493
Drug: bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.